Cargando…

Ibrutinib repurposing: from B-cell malignancies to solid tumors

Detalles Bibliográficos
Autores principales:	Massó-Vallés, Daniel, Jauset, Toni, Soucek, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965256/ https://www.ncbi.nlm.nih.gov/pubmed/27489860 http://dx.doi.org/10.18632/oncoscience.310

Ejemplares similares

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
por: Massó-Vallés, Daniel, et al.
Publicado: (2020)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023)

Targets for Ibrutinib Beyond B Cell Malignancies
por: Berglöf, A., et al.
Publicado: (2015)

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
por: Muñoz, Javier, et al.
Publicado: (2023)

Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation
por: Zhang, Qing, et al.
Publicado: (2018)

Correction to: Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
Publicado: (2023)

Repurposing ibrutinib: therapeutic effects and implications for translational approaches in Alzheimer’s disease
por: Lee, Hyun-ju, et al.
Publicado: (2023)

Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
por: Szklener, Katarzyna, et al.
Publicado: (2022)

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
por: Yu, Yingyan
Publicado: (2021)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
por: Zacarías-Fluck, Mariano F., et al.
Publicado: (2023)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review
por: Metzler, Julian Matthias, et al.
Publicado: (2020)

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2016)

Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19
por: Kaliamurthi, Satyavani, et al.
Publicado: (2021)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
por: Tavallai, Mehrad, et al.
Publicado: (2016)

PU.1 is a tumor suppressor for B cell malignancies
por: Okuno, Yutaka, et al.
Publicado: (2012)

Inhibition of effector B cells by ibrutinib in systemic sclerosis
por: Einhaus, Jakob, et al.
Publicado: (2020)

Enhancing B-Cell Malignancies—On Repurposing Enhancer Activity towards Cancer
por: Kasprzyk, Marta Elżbieta, et al.
Publicado: (2021)

Metastasis and Tumor Cell Migration of Solid Tumors
por: Hoeppner, Jens, et al.
Publicado: (2021)

Repurposing Tecfidera for cancer
por: Booth, Laurence, et al.
Publicado: (2016)

Reverse Cholesterol Transport of Macrophages Repurposed for Hepatitis B Virus Entry
por: Cheng, Yun, et al.
Publicado: (2023)

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
por: Annibali, Daniela, et al.
Publicado: (2014)

The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets
por: Zacarías-Fluck, Mariano F, et al.
Publicado: (2021)

Repurposing Tuft Cells to Suppress Pancreatic Cancer
por: Means, Anna L.
Publicado: (2020)

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue
por: Beaulieu, Marie-Eve, et al.
Publicado: (2023)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Ibrutinib in B-cell lymphoma: single fighter might be enough?
por: Xue, Chao, et al.
Publicado: (2020)

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
por: George, Bhawana, et al.
Publicado: (2020)

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
por: Shadman, Mazyar, et al.
Publicado: (2023)

Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib
por: Messina, Julia A., et al.
Publicado: (2017)

Immunotherapy for Solid Tumors
por: de Saint Basile, Hortense, et al.
Publicado: (2023)

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
por: He, Yizi, et al.
Publicado: (2019)

Repurposing ARBs as treatments for breast cancer
por: George, Amee J., et al.
Publicado: (2017)

Drug repurposing strategies for COVID-19
por: Senanayake, Suranga L
Publicado: (2020)

Repurposing Canagliflozin to target brain aging
por: Jayarathne, Hashan, et al.
Publicado: (2023)

Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wang, Jinjin, et al.
Publicado: (2020)

288. Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies after Anticancer Therapy Which Included Ibrutinib
por: Malek, Alexandre, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6mhng7a189d24nm2fbj31mhn13